Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Gabapentin Market Revenue Growth On Track For A 8.1% CAGR Through 2030
The gabapentin market has experienced robust expansion over the past few years. It is projected to expand from $3.01 billion in 2025 to $3.26 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. The historical growth of this market can be attributed to the increasing adoption of epilepsy treatments, the widespread prevalence of neuropathic pain, the accessibility of generic drugs, prevailing physician prescribing patterns, and the rising burden of chronic diseases.
The gabapentin market is projected to experience robust expansion over the coming years. Its valuation is expected to reach $4.45 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This anticipated growth during the forecast period is attributable to factors such as an increasing aging population, the rise in diabetic neuropathy, wider generic drug penetration, advancements in outpatient pain management, and the growth of telemedicine prescriptions. Prominent trends expected in this period include a heightened application in neuropathic pain management, an increased preference for generic formulations, the broadening of chronic pain treatment programs, the evolution of oral solid dosage forms, and an uptick in prescriptions for neurological disorders.
Get A Free Sample Report With In-Depth Market Insights:
Gabapentin Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The rising incidence of epilepsy is anticipated to propel the expansion of the gabapentin market in the future. This neurological condition, epilepsy, involves recurrent seizures resulting from abnormal electrical signals in the brain. The surge in epilepsy cases is primarily linked to an expanding older demographic, as advanced age elevates the likelihood of neurological ailments leading to seizures. Gabapentin manages epilepsy by moderating atypical nerve impulses within the brain and diminishing signals that trigger seizures. Its mechanism involves targeting calcium channels to aid in averting seizure episodes. For example, data from February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, indicates that approximately 50 million individuals worldwide suffer from epilepsy, with nearly 80% residing in low- and middle-income nations, and as many as 70% could achieve a seizure-free life through adequate diagnosis and treatment. Annually, an estimated 5 million people globally receive a new diagnosis of epilepsy; this rate stands at around 49 per 100,000 in high-income countries, whereas it can reach 139 per 100,000 in low- and middle-income countries. Consequently, the expanding incidence of epilepsy is fueling the growth of the gabapentin market.
Gabapentin Market Segment Performance And Emerging Opportunities
The gabapentin market covered in this report is segmented –
1) By Type: Generic, Branded
2) By Dosage Form: Tablet, Capsule, Oral Solution
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications
Subsegments:
1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution
2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations
Gabapentin Market Innovation Trends Shaping Future Development
Leading companies in the gabapentin market are concentrating on developing advanced formulations, such as bioequivalent tablets, to enhance therapeutic efficacy and broaden treatment options for neurological conditions. Bioequivalent tablets are generic medications designed to release an identical dose of the active ingredient into the bloodstream with the same speed and efficiency as the branded version, guaranteeing similar safety and therapeutic effects. For instance, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, introduced Gabapentin Tablets USP in 600 mg and 800 mg strengths, following approval from the United States Food & Drug Administration (USFDA), to expand its neurology portfolio in the US market. This innovative gabapentin product features enhanced bioavailability, precise dosing, and patient-friendly administration, facilitating more consistent therapeutic outcomes, improved symptom control, and greater convenience for long-term therapy. Gabapentin tablets USP, 600 mg, offer versatile therapeutic potential, providing effective management for a range of neurological conditions like neuropathic pain and partial seizures through reliable dosing and proven clinical efficacy.
Gabapentin Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC
View The Full Gabapentin Market Report:
Gabapentin Market Largest Region By Revenue And Market Share
North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
